$289.59 Million in Sales Expected for Insulet Co. (NASDAQ:PODD) This Quarter

Equities research analysts expect Insulet Co. (NASDAQ:PODD – Get Rating) to post sales of $289.59 million for the current fiscal quarter, according to Zacks. Seven analysts have made estimates for Insulet’s earnings, with estimates ranging from $286.40 million to $301.30 million. Insulet reported sales of $263.20 million during the same quarter last year, which indicates a positive year over year growth rate of 10%. The firm is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Insulet will report full year sales of $1.23 billion for the current year, with estimates ranging from $1.22 billion to $1.27 billion. For the next financial year, analysts expect that the firm will report sales of $1.50 billion, with estimates ranging from $1.47 billion to $1.54 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Insulet.

Insulet (NASDAQ:PODD – Get Rating) last posted its quarterly earnings results on Thursday, May 5th. The medical instruments supplier reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.17. The business had revenue of $295.40 million during the quarter, compared to analysts’ expectations of $287.99 million. Insulet had a net margin of 3.91% and a return on equity of 15.81%. The company’s quarterly revenue was up 17.1% on a year-over-year basis.

Several research analysts recently issued reports on the stock. Robert W. Baird reduced their target price on shares of Insulet from $315.00 to $275.00 in a report on Thursday, February 24th. Bank of America assumed coverage on shares of Insulet in a report on Wednesday, March 2nd. They set a “buy” rating for the company. Piper Sandler reduced their target price on shares of Insulet from $295.00 to $230.00 and set a “neutral” rating for the company in a report on Thursday, February 24th. StockNews.com assumed coverage on shares of Insulet in a report on Thursday, March 31st. They set a “hold” rating for the company. Finally, BTIG Research raised shares of Insulet from a “neutral” rating to a “buy” rating and set a $320.00 target price for the company in a report on Thursday, February 3rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of “Buy” and a consensus price target of $296.86.

In other news, CEO Shacey Petrovic sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, April 4th. The stock was sold at an average price of $273.25, for a total value of $4,098,750.00. Following the transaction, the chief executive officer now owns 13,607 shares in the company, valued at $3,718,112.75. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Wayde D. Mcmillan sold 1,455 shares of Insulet stock in a transaction that occurred on Friday, April 1st. The stock was sold at an average price of $275.60, for a total value of $400,998.00. Following the completion of the sale, the chief financial officer now directly owns 21,354 shares in the company, valued at $5,885,162.40. The disclosure for this sale can be found here. 0.90% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC acquired a new stake in Insulet in the 4th quarter valued at about $203,619,000. Capital Research Global Investors increased its holdings in shares of Insulet by 8.0% in the fourth quarter. Capital Research Global Investors now owns 7,811,512 shares of the medical instruments supplier’s stock valued at $2,078,434,000 after purchasing an additional 579,764 shares during the last quarter. Norges Bank purchased a new position in Insulet during the fourth quarter worth approximately $146,269,000. Marshall Wace LLP acquired a new position in Insulet during the fourth quarter worth $140,781,000. Finally, William Blair Investment Management LLC purchased a new stake in Insulet in the 1st quarter valued at $136,901,000.

NASDAQ PODD opened at $200.03 on Wednesday. The company has a fifty day simple moving average of $242.97 and a two-hundred day simple moving average of $257.39. The stock has a market cap of $13.87 billion, a P/E ratio of 317.51 and a beta of 0.72. Insulet has a 12-month low of $181.00 and a 12-month high of $324.81. The company has a current ratio of 5.98, a quick ratio of 4.51 and a debt-to-equity ratio of 3.11.

About Insulet (Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

Featured Stories